

Les données scientifiques : articles originaux

Bibliography: original articles

1. Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. Groyer E, Nicoletti A, Ait-Oufella H, Khallou-Laschet J, Varthaman A, Gaston AT, Thauinat O, Kaveri SV, Blatny R, Stockinger H, Mallat Z, Caligiuri G. **J Am Coll Cardiol.** 2007 Jul 24;50(4):344-50. Epub 2007 Jul 6.
2. Late introduction of sirolimus induces anemia in renal transplant recipients. Thauinat O, Beaumont C, Lechaton S, Kreis H, Morelon E. **Transplantation.** 2007 May 15;83(9):1283; author reply 1284.
3. Is lymphoid neogenesis a therapeutic target for chronic rejection? Thauinat O, Patey N, Michel JB, Nicoletti A. **Am J Transplant.** 2007 May;7(5):1312-3; author reply 1314
4. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Servais A, Meas-Yedid V, Buchler M, Morelon E, Olivo-Marin JC, Lebranchu Y, Legendre C, Thervet E. **Transplantation.** 2007 Dec 27;84(12):1595-601.
5. Outcomes 18 months after the first human partial face transplantation. Dubernard JM, Lengelé B, Morelon E, Testelin S, Badet L, Moure C, Beziat JL, Dakpé S, Kanitakis J, D'Hauthuille C, El Jaafari A, Petruzzo P, Lefrançois N, Taha F, Sirigu A, Di Marco G, Carmi E, Bachmann D, Cremades S, Giroux P, Burloux G, Hequet O, Parquet N, Francès C, Michallet M, Martin X, Devauchelle B. **N Engl J Med.** 2007 Dec 13;357(24):2451-60.
6. High pretransplantation soluble CD30 levels: impact in renal transplantation. Giannoli C, Bonnet MC, Perrat G, Houillon A, Reydet S, Pouteil-Noble C, Villar E, Lefrançois N, Morelon E, Dubois V. **Transplant Proc.** 2007 Oct;39(8):2574-5.
7. "Facial graft": about the first facial allotransplantation of composite tissues. Lengelé BG, Testelin S, Dakpe S, Carton S, Beziat JL, Badet L, Morelon E, Dubernard JM, Devauchelle B. **Ann Chir Plast Esthet.** 2007 Oct;52(5):475-84. Epub 2007 Aug 24. French.
8. Absence of c4d deposition in human composite tissue (hands and face) allograft biopsies: an immunoperoxidase study. Kanitakis J, McGregor B, Badet L, Petruzzo P, Morelon E, Devauchelle B, Dubernard JM. **Transplantation.** 2007 Jul 27;84(2):265-7.
9. Angioedema in renal transplant recipients on sirolimus. Mahé E, Morelon E, Lechaton S, Kreis H, de Prost Y, Bodemer C. **Dermatology.** 2007;214(3):205-9.
10. Effect of ischaemic preconditioning and vitamin C on functional recovery of ischaemic kidneys. Mahfoudh-Boussaid A, Badet L, Zaouali A, Saidane-Mosbahi D, Miled A, Ben Abdennebi H. **Prog Urol.** 2007 Jun;17(4):836-40. French.
11. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Badet L, Benhamou PY, Wojtuszczyz A, Baertschiger R, Milliat-Guittard L, Kessler L, Penfornis A, Thivolet C, Renard E, Bosco D, Morel P, Morelon E, Bayle F, Colin C, Berney T; GRAGIL Group. **Transplantation.** 2007 Jul 15;84(1):89-96.
12. Left radical nephrectomy in two patients with portal hypertension and splenorenal venous shunt. Fassi-Fehri H, Zakaria Y, Marechal JM, Marcotte G, Colombel M, Martin X, Badet L. **Prog Urol.** 2007 Feb;17(1):101-4. French.
13. National prospective survey on the surgical quality of renal transplants in France. Study conducted by the Association Française d'Urologie ransplantation Committee; Verhoest G, Salomon L, Barrou B, Bensalah K, Guille F, Lobel B, Petit J, Boutin JM, Descotes JL, Dore B, Staerman F, Benoit G, Badet L, Hubert J, Lechevallier E, Patard JJ; Comité de Transplantation Association Française d'Urologie. **Prog Urol.** 2007 Feb;17(1):54-9. French.
14. Efficacy of the InVance male sling in men with stress urinary incontinence. Fassi-Fehri H, Badet L, Cherass A, Murat FJ, Colombel M, Martin X, Gelet A.. **Eur Urol.** 2007 Feb;51(2):498-503. Epub 2006 Sep 7.
15. Bilateral hand transplantation: six years after the first case. Petruzzo P, Badet L, Gazarian A, Lanzetta M, Parmentier H, Kanitakis J, Sirigu A, Martin X, Dubernard JM. **Am J Transplant.** 2006 Jul;6(7):1718-24.
16. Granulomatous renal masses following intravesical bacillus Calmette Guérin therapy: the central unaffected calyx sign. Senés AT, Badet L, Lyonnet D, Rouvière O. **Br J Radiol.** 2007 Oct;80(958):e230-3.
17. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. Couderc BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M. **J Clin Oncol.** 2007 Jul 1;25(19):2678-84. Epub 2007 May 21. Erratum in: J Clin Oncol. 2007 Nov 1;25(31):5048.
18. Control of prostate cancer by transrectal HIFU in 227 patients. Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A.. **Eur Urol.** 2007 Feb;51(2):381-7. Epub 2006 May 2.
19. Efficient generation of CD34+ progenitor-derived dendritic cells from G-CSF-mobilized peripheral mononuclear cells does not require hematopoietic stem cell enrichment. Paczesny S, Li YP, Li N, Latger-Cannard V, Marchal L, Ou-Yang JP, Bordigoni P, Stoltz JF, Eljaafari A. **J Leukoc Biol.** 2007 Apr;81(4):957-67. Epub 2007 Jan 17.
20. Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity. Li N, Feugier P, Serrurier B, Latger-Cannard V, Lesesve JF, Stoltz JF, Eljaafari A. **Exp Hematol.** 2007 Mar;35(3):507-15
21. Enteric glia inhibits intestinal epithelial cell proliferation partly through a TGF-beta1-dependent pathway. M. Neunlist, P. Aubert, S. Bonnaud, L. Van Landeghem, E. Coron, T. Wedel, P. Naveilhan, A. Ruhl, B. Lardeux, T. Savidge, F. Paris & J.P. Galmiche. **Am J Physiol-Gastr. L.** 2007, **292** : G231-G241. [IF-2006 (3.681)]
22. Bilateral Deep Brain Stimulation of the Globus Pallidus to Treat Tardive Dyskinesia. P. Damier, S. Thobois, T. Witjas, E. Cuni, P. Derost, S. Raoul, P. Mertens, J.C. Peragut, J.J. Lemaire, P. Burbaud, J.M. Nguyen, P.M. Llorca & O. Rascol. **Arch. Gen. Psychiat.** 2007, **64** : 170-176. [IF-2006 (13.936)]
23. Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases. P. Miqueu, M. Guillet, N. Degauque, J.-C. Doré, J.-P. Soullillou & S. Brouard. **Mol. Immunol.** 2007, **44** : 1057-1064. [IF-2006 (4.768)]
24. Multiparameter immune profiling of operational tolerance in liver transplantation. M. Martinez-Llordella, I. Puig-Pey, G. Orlando, M. Ramoni, G. Tisone, A. Rimola, J. Lerut, D. Latinne, C. Margarit, I. Bilbao, S. Brouard, M. Hernandez-Fuentes, J.-P. Soullillou & A. Sanchez-Fueyo. **Am. J. Transplant.** 2007, **7** : 309-319. [IF-2006 (6.843)]
25. Expression and release of soluble HLA-E feature endothelial cell activation and vascular inflammation. S. Coupel, A. Moreau, M. Hamidou, V. Horejsi, J.P. Soullillou & B. Charreau. **Blood.** 2007, **109** : 2806-2814. [IF-2006 (10.37)]
26. Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation. C. Séveno, F. Coulon, F. Haspot, E. Mérieau, K. Renaudin, B. Martinet & B. Vanhove. **Xenotransplantation.** 2007, **14** : 25-33. [IF-2006 (1.777)]

Articles originaux (Suite)

Bibliography (Cont.)

27. Acute humoral rejection of renal transplants in alloimmunized pigs. N. Poirier, F. Maillat, M.-L. Barussaud, K. Renaudin, J. Ashton-Chess, D. Minault, J. Hervouet, J. P. Souillou & G. Blancho. **J. Surg. Res.** 2007, **139** : 261-268. [IF-2006 (2.038)]
28. Development of CD25⁻ regulatory T cells following heart transplantation; evidence for transfer of long term survival. N. Degauque, D. Lair, C. Braudeau, F. Haspot, F. Sébille, A. Dupont, E. Merieau, S. Brouard & J.P. Souillou. **Eur. J. Immunol.** 2007, **37** : 147-156. [IF-2006 (4.772)]
29. Functional compartmentalization following induction of long-term graft survival with pre-graft donor-specific transfusion. D. Lair, N. Degauque, P. Miqueu, V. Jovanovic, M. Guillet, E. Mérieau, A. Moreau, J.P. Souillou & S. Brouard. **Am. J. Transplant.** 2007, **7** : 538-549. [IF-2006 (6.843)]
30. TLR9 ligand enhances proliferation of rat CD4⁺ T cell and modulates suppressive activity mediated by CD4⁺ CD25⁺ T cell. E. Chiffolleau, J.M. Heslan, M. Heslan, C. Louvet, T. Condamine & M.C. Cuturi. **Int. Immunol.** 2007, **19** : 193-201. [IF-2006 (4.015)]
31. Long-term cell monitoring of kidney recipients following an antilymphocyte globulin induction with and without steroids. S. Louis, M. Audrain, D. Cantarovich, B. Schaffrath, K. Hofmann, U. Janssen, C. Ballet, S. Brouard & J.P. Souillou. **Transplantation.** 2007, **83** : 712-721. [IF-2006 (3.972)]
32. Effect of brain dead donor resuscitation on delayed graft function. Results of a monocentric analysis. M. Giral, J.P. Bertola, Y. Foucher, D. Villers, E. Bironneau, Y. Blanloeil, G. Karam, P. Daguin, L. Lerat & J.P. Souillou. **Transplantation.** 2007, **83** : 1174-1181. [IF-2006 (3.972)]
33. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. N. Kamar, L. Frimat, G. Blancho, P. Wolff, M. Delahousse & L. Rostaing. **Transplant. Int.** 2007, **20** : 128-134. [IF-2006 (2.146)]
34. Specific humoral rejection of a pancreas allograft in a recipient of a pancreas after kidney transplantation. R. Carbajal, G. Karam, K. Renaudin, F. Maillat, A. Cesbron, L. Rostaing, D. Cantarovich, J.P. Souillou & G. Blancho. **Nephrol. Dial. Transpl.** 2007, **22** : 942-944. [IF-2006 (3.154)]
35. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. N. Gong, U. Pleyer, K. Vogt, I. Anegon, A. Flügel, H-D.Volk & T. Ritter. **Invest. Ophthalm. Vis. Sci.** 2007, **48** : 1043-1052. [IF-2005 (3.643)]
36. Rat model of Parkinson's disease with bilateral motor abnormalities reversible with levodopa, and dyskinesias. V. Paillé, V. Henry, L. Lescaudron, P. Brachet & P. Damier. **Movement Disord.** 2007, **22** : 533-539. [IF-2005 (2.83)]
37. CD40lg treatment results in allograft acceptance mediated by CD8⁺CD45RClow T cells, IFN-gamma, and indoleamine 2,3 dioxygenase. C. Guillonnet, M. Hill, F.-Xavier Hubert, E. Chiffolleau, C. Hervé, X.L. Li, M. Heslan, C. Usal, L. Tesson, S. Ménoret, A. Saoudi, B. Le Mauff, R. Josien, M.C. Cuturi & I. Anegon. **J Clin Invest.** 2007, **117**: 1096-1106. [IF-2006 (15.754)]
38. The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease. N.D. Dey, A.J. Boersen, R.A. Myers, L.R. York, M.C. Bombard, M. Lu, M.I. Sandstrom, V.D Hulce, L. Lescaudron & G.L. Dunbar. **Restor Neurol Neuros.** 2007, **25** : 485-492. [IF-2006 (2.862)]
39. A semi-Markov model for multistate and interval-censored date with multiple terminal events. Application in renal transplantation. Y. Foucher, M. Giral, J.-P. Souillou & J.-P. Daures. **Stat Med.** 2007, **26** : 5381-5393. [IF-2006 (1.737)]
40. Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. T. Haudebourg, A.-S. Dugast, F. Coulon, C. Usal, F. Triebel & B. Vanhove. **Transplantation.** 2007, **84** : 1500-1506. [IF-2006 (3.972)]
41. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. S. Brouard, E. Mansfield, C. Braud, L. Li, M. Giral, S.-C. Hsieh, D. Baeten, M. Zhang, J. Ashton-Chess, C. Braudeau, F. Hsieh, A. Dupont, A. Pallier, A. Moreau, S. Louis, C. Ruiz, O. Salvatierra, J.-P. Souillou & M. Sarwal. **P Natl Acad Sci Usa.** 2007, **104** : 15448-15453. [IF-2006 (9.643)]
42. Role of IFN γ in allograft tolerance mediated by CD4⁺CD25⁺ regulatory T cells by induction of IDO in endothelial cells. P. Thébaud, T. Condamine, M. Heslan, M. Hill, I. Bernard, A. Saoudi, R. Josien, M.-C. Cuturi & E. Chiffolleau. **Am J Transplant.** 2007, **7** : 2472-2482. [IF-2006 (6.843)]
43. A role for heme oxygenase - 1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. D. Chabannes, M. Hill, E. Merieau, J. Rossignol, R. Brion, J.-P. Souillou, I. Anegon & M.-C. Cuturi. **Blood.** 2007, **110** : 3691-3694. [IF-2006 (10.37)]
44. Indoleamine 2,3-dioxygenase expands human CD4⁺CD25^{high} regulatory T cells by promoting maturation of LPS-treated dendritic cells. M. Hill, S. Tanguy-Royer, P. Royer, C. Chauveau, K. Asghar, L. Tesson, F. Lavainne, S. Remy, R. Brion, F.-X. Hubert, M. Heslan, M. Rimbart, L. Berthelot, J.R. Moffett, R. Josien, M. Grégoire & I. Anegon. **Eur J Immunol.** 2007, **37** : 3054-3062. [IF-2006 (4.772)]
45. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. P. Friend, G. Russ, R. Oberbauer, M.G. Murgia, G. Tufveson, J. Chapman, G. Blancho, A. Mota, G. Grandaliano, J.M. Campistol, Y. Brault & J.T. Burke. **Transpl Int.** 2007, **20** : 754-760. [IF-2006 (2.146)]
46. Nitric oxide and indoleamine 2,3-dioxygenase mediate CTLA4lg-induced survival of heart allografts in rats. M. Hill, R. Zagani, C. Voisine, C. Usal & I. Anegon. **Transplantation.** 2007, **84** : 1060-1063. [IF-2006 (3.972)]
47. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40lg-treated heart allograft recipients. C. Guillonnet, C. Séveno, A.-S. Dugast, K. Renaudin, F. Haspot, C. Usal, J. Veziers, I. Anegon & B. Vanhove. **J Immunol.** 2007, **179** : 8164-8171. [IF-2006 (6.293)]
48. Immunosuppression minimization in kidney transplantation. D. Cantarovich, F. Vistoli & J.-P. Souillou. **Front Biosci.** 2007. (in press) [IF-2006 (2.771)]
49. Impact of surgical procedures and complications on outcomes of third and subsequent kidney transplants. Loupy, D. Anglicheau, M.O. Timsit, E. Thervet, M.F. Mamzer, F. Martinez, F. Desgrandchamps, N. Thiounn, H. Kreis, Ch. Legendre, Y. Chrétien, A. Méjean. **Transplantation.** 2007, **83** : 385-91. (IF = 3,972)
50. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy : a multivariate analysis of results at 5 years. Ch. Legendre, Y. Brault, J.M. Morales, R. Oberbauer, P. Altieri, H. Riad, J. Mahony, M. Messina, B. Pussell, J. Martinez, M. Lelong, J.T. Burke from the Rapamune Maintenance Regimen Study Group. **Clinical Transplantation.** 2007, **21** : 330-336.
51. Post-transplant prophylactic intravenous immunoglobulin in high-immunological risk kidney transplant recipients : a pilot study. D. Anglicheau, A. Loupy, C. Suberbielle, J. Zuber, R. Cavalcanti, M. Le Quintrec, F. Audat, F. Martinez, M.F. Mamzer-Bruneel, E. Thervet, Ch. Legendre. **Am J Transplant.** 2007, **7** : 1195-92. (IF = 6,843)

Articles originaux (Suite)

Bibliography (Cont.)

52. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids : results of follow up to 30 months post-transplant. G. Mourad, A. Karras, N. Kamar, V. Garrigue, Ch. Legendre, N. LeFrançois, B. Charpentier, B. Bourbigot, C. Pouteil-Noble, F. Bayle, Y. lebranchu, C. Mariat, Y. le Meur, M. Kessler, B. Moulin, D. Ducloux, M. Delahousse, P. Lang, P. Merville, K. Chaouche-Teyara, L. Rostaing from the French Myriade FRO1 Study Group. **Clinical Transplantation**. 2007, **21** : 295-300.
53. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients : pooled data from three 12-month multicenter, open-label, prospective studies. Ch. Legendre, D. Cohen, M. Zeier, L. Rostaing, K. Budde. **Transplant Proc**. 2007, **39** :1386-91.
54. To biopsy or not to biopsy ? Should we screen the histology of stable renal grafts ? O. Thaumat, Ch. Legendre, E. Morelon, H. Kreis, M.F. Mamzer-Bruneel. **Transplantation**. 2007, **84** :671-76. (IF = 3,972)
55. High sirolimus levels may induce focal segmental glomerulosclerosis. E. Letavernier, P. Bruneval, C. Mandet, J.P. Duong Van Huyen, M.N. Péraldi, I. Helal, L.H. Noël, Ch. Legendre. **Clin J Am Soc Nephrol**. 2007, **2** :326-33.
56. 5% topical imiquimod tolerance in transplant recipients. L. Ben M'barek, A. Mebazaa, S. Euvrard, C. Frances, E. Thervet, P. Morel, S. Menasche, Ch. Legendre, C. Lebbé. **Dermatology**. 2007, **215** :130-3.
57. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Servais, V. Meas-Yedid, M. Buchler, E. Morelon, J.C. Olivo-Marin, Y. Lebranchu, Ch. Legendre, E. Thervet. **Transplantation**. 2007, **84** :1595-1601. (IF = 3,972)
58. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients. from retrospective analyses to prospective studies. Anglicheau D, Ch. Legendre, E. Thervet. **Transplantation Proceedings**. 2007, **39** :2142-4.
59. Long term outcome of third kidney transplants. Loupy, D. Anglicheau, C. Suberbielle, A. Méjean, F. Martinez, M.F. Mamzer-Bruneel, J. Zuber, N. Thiounn, H. Kreis, E. Thervet, Ch. Legendre. **Nephrol Dial Transplant**. 2007, **22** :2693-700. (IF = 3,154)
60. Cyclosporine abrogates de novo generation of Tregs independantly of IL-2. J. Zuber, A. Brodin-Sartorius, E. Thervet, Ch. Legendre. **Am J Transplant**. 2007, **7** :2645. (IF = 6,843)
61. Cytochrome P450 3A polymorphisms and immunosuppressive drugs : an update. D. Anglicheau, Ch. Legendre, P. Beaune, E. Thervet. **Pharmacogenomics**. 2007, **8** :835-849
62. CD3-specific antibodies: a portal to the treatment of autoimmunity. Chatenoud L, Bluestone JA. **Nat Rev Immunol**. 2007, **7**:622-32.
63. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. **Proc Natl Acad Sci U S A**. 2007, **104**:6335-40.
64. One step towards restoration of self-tolerance in human autoimmune diseases. Chatenoud L. **Med Sci (Paris)** 2007, **23**:167-71.
65. Thyroiditis and gluten intolerance: extrapancreatic auto-immune diseases associated with type 1 diabetes. Faesch S, Jennane F, Izembart I, Chatenoud L, Taupin P, Martin D, Polak M, Robert J.J. **Arch Pediatr**. 2007, **14**:24-30.
66. Towards cell-based therapy of type 1 diabetes. Kabelitz D, Geissler EK, Soria B, Schroeder IS, Fändrich, Chatenoud L. (2008) **Trends in Immunol**. (sous presse)
67. Chemical Immunosuppression in Islet Transplantation - Friend or Foe? Chatenoud L (2008) **N Engl J Med** **358**;1192-93
68. P450 3A polymorphisms and immunosuppressive drugs: an update. Anglicheau D, Legendre C, Beaune P, Thervet E. **Cytochrome Pharmacogenomics**. 2007, Jul;**8**(7):835-49.
69. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Servais A, Meas-Yedid V, Buchler M, Morelon E, Olivo-Marin JC, Lebranchu Y, Legendre C, Thervet E. **Transplantation**. 2007, Dec 27;**84**(12):1595-601.
70. Quantification of interstitial fibrosis by image analysis on routine renal biopsy 1 year after transplantation in patients managed by C2 monitoring of cyclosporine microemulsion. Servais A, Meas-Yedid V, Buchler M, Morelon E, Olivo-Marin JC, Thervet E. **Transplant Proc**. 2007, Oct;**39**(8):2560-2.
71. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, de Ligny BH, Rostaing L, Thervet E, Szlag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. **Am J Transplant**. 2007, Nov;**7**(11):2496-503. Epub 2007 Oct 1.
72. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Anglicheau D, Legendre C, Thervet E. **Transplant Proc**. 2007, Sep;**39**(7):2142-4.
73. Cyclosporine abrogates de novo generation of Tregs independently of IL-2. Zuber J, Brodin-Sartorius A, Thervet E, Legendre C. **Am J Transplant**. 2007, Nov;**7**(11):2645; author reply 2646. Epub 2007 Sep 14. No abstract available.
74. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Büchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, Hurault de Ligny B, Le Meur Y, Thierry A, Villemain F, Heng AE, Moulin B, Morin MP, Noël C, Lebranchu Y; SPIESSER Group. **Am J Transplant**. 2007, Nov;**7**(11):2522-31. Epub 2007 Sep 14.
75. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Ben M'barek L, Fardet L, Mebazaa A, Thervet E, Biet I, Kérob D, Morel P, Lebbe C. **Dermatology**. 2007, **215**(3):202-5.
76. 5% topical imiquimod tolerance in transplant recipients. Ben M'barek L, Mebazaa A, Euvrard S, Frances C, Thervet E, Morel P, Menasché S, Legendre C, Lebbe C. **Dermatology**. 2007, **215**(2):130-3.
77. Successful organ transplantation after treatment of fatal cyanide poisoning with hydroxocobalamin. Fortin JL, Ruttimann M, Capellier G, Bigorie A, Ferlicot S, Thervet E. **Clin Toxicol (Phila)**. 2007, Jun-Aug;**45**(5):468-71.
78. Long-term outcome of third kidney transplants. Loupy A, Anglicheau D, Suberbielle C, Méjean A, Martinez F, Zuber J, Mamzer-Bruneel MF, Kreis H, Thervet E, Thiounn N, Legendre C. **Nephrol Dial Transplant**. 2007, Sep;**22**(9):2693-700. Epub 2007 Apr 23.
79. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Anglicheau D, Loupy A, Suberbielle C, Zuber J, Patey N, Noël LH, Cavalcanti R, Le Quintrec M, Audat F, Méjean A, Martinez F, Mamzer-Bruneel MF, Thervet E, Legendre C. **Am J Transplant**. 2007, May;**7**(5):1185-92. Epub 2007 Mar 12.
80. Impact of surgical procedures and complications on outcomes of third and subsequent kidney transplants. Loupy A, Anglicheau D, Timsit MO, Thervet E, Mamzer-Bruneel MF, Martinez F, Desgranchamps F, Thiounn N, Kreis H, Legendre C, Chrétien Y, Méjean A. **Transplantation**. 2007, Feb 27;**83**(4):385-91.

Les conférences internationales invitées

Invited international communications

- ▶ Composite tissues allografts in man and Treatment of prostate cancer with focalized ultrasound. International symposium of Urological society of Chili. Juin 2007. X Martin.
- ▶ Prélèvement de reins sur donneur à cœur arrêtés. Congrès annuel de la Société de Néphrologie. Septembre 2007. L Badet.
- ▶ Lyon experience in Hand transplantation. International congress of CTA. Innsbruck. September 2007. L Badet.
- ▶ Greffe combinée de CSH et greffe de face. 22èmes Ateliers de Thérapies Cellulaires et Génique. Bruxelles. Octobre 2007. E Morelon.
- ▶ Mode of action and side effects of mTOR inhibitors. ESOT-Hesperis course. Saint Gallen. Switzerland. Novembre 2007. E Morelon.
- ▶ Transplantation rénale chez des receveurs obèses. Congrès de l'Association Française d'Urologie. Novembre 2007. L Badet.
- ▶ Long term effects of pancreas transplantation. Congres Francophone de Transplantation. Décembre 2007. X Martin
- ▶ Homing of FoxP3+ T cells from graft to blood in a face grafted patient may account for occurrence of a rejection episode one month after infra-clinical CMV infection, as assessed by CCR4, and CLA mRNA expression kinetics. International Symposium on Composite Tissue Allograft. Innsbruck. A. Eljaafari.
- ▶ Immunosuivi moléculaire de patients ayant subi une greffe de tissus composites : Importance des messagers de FoxP3, perforine et des récepteurs de chemokine à tropisme cutané. Société Francophone de Thérapie cellulaire. Lyon. A. Eljaafari.
- ▶ Rejet chronique : leçons tirées des modèles expérimentaux. Club de la transplantation. Abbaye des Vaulx de Cernay. O. Thauinat.
- ▶ Néogenèse lymphoïde et rejet chronique. Société Française de Néphrologie. Lyon. O. Thauinat.
- ▶ L'artériosclérose du greffon. Société Francophone de Transplantation. Lyon. O Thauinat.
- ▶ Composite Tissue Allograft update. American Association of Hand Surgery. Puerto Rico (USA) January 2007. JM Dubernard.
- ▶ Hand transplantation. International Transplantation meeting IENA. Germany. February 2007. JM Dubernard.
- ▶ Hand transplantation: immunological challenges. 15th Brussels, International Symposium. Février 2007. JM Dubernard.
- ▶ Multitissue and HSC co-transplantation. European Bone Marrow Transplantation Congress. Lyon (France). JM Dubernard.
- ▶ Transplantation = from myth to reality. Semaine de la France en Islande. Island. Mars 2007. JM Dubernard
- ▶ De la greffe cellulaire (Beta) aux tissus composites. Université de Liège. Mars 2007. JM Dubernard.
- ▶ Results and challenges in transplantation of composite tissue. Congrès Brésilien de Transplantation. Florianopolis, Septembre 2007. JM Dubernard.
- ▶ Evolving from organs to tissue transplantation an historico analyses. Congrès Brésilien de Transplantation. Florianopolis, Septembre 2007. JM Dubernard.
- ▶ Keynote address: transplantation defining the future. Transplant summit 2007: defining the future. Chicago. Septembre 2007. JM Dubernard.
- ▶ Comparaison du visage et de la main. Symposium international, rencontres philosophes et chercheurs. Université Paris VII. Octobre 2007. JM Dubernard.
- ▶ Transplantation pancréatique : comparaison drainage veineux systémiques et porte. Pancreas transplantation in Belgium, 25 years. Liège. Novembre 2007. JM Dubernard.
- ▶ Greffes composites, médecine régénératrice et éthique. Entretien Jacques Cartier (France-Quebec). Lyon. Décembre 2007. JM Dubernard.
- ▶ "Target concentrations or range according to the type of organ transplanted, time post-transplantation and co-medication, dose" European Consensus Conference on tacrolimus, Brussels, May 2007. E. Thervet.
- ▶ "Surrogate markers for prediction of outcome in transplantation - The impact of gene polymorphism on the management and understanding of long-term graft outcome" NAT, Nantes, June 2007. E. Thervet.
- ▶ "Role of pharmacogenetics of Immunosuppressive drugs in organ transplantation" IATDMCT, Nice, 2007 E. Thervet.
- ▶ "Chronic Allograft Nephropathy beyond histology" ESOT Prague 2007. C. Legendre
- ▶ "New immunosuppressive drugs and Routine Biopsies" Malmö 07 - "Routine biopsies." St Galle - Hespéris Enseignement Européen. C. Legendre.
- ▶ "Resetting the capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance" 9th Congress of the Catalane Society of Transplantation. Barcelona, Spain, February 2007. L. Chatenoud.
- ▶ "Adaptive regulatory T cells control the progression of autoimmunity" Keystone symposia. Vancouver, Canada. February 2007 L. Chatenoud.
- ▶ "New methods to preserve beta-cell mass in type 1 diabetes" 12th day of Diabetes in children and teenagers of the Spanish society of the pediatric endocrinology. Sevilla, Spain. February 2007. L. Chatenoud.
- ▶ "Adaptative versus Natural Regulatory T cells in the control of autoimmunity. 2nd interdisciplinary MS Experts Workshop. Berlin, Germany. March 2007. L. Chatenoud.
- ▶ "T-cell control of autoimmune diabetes" Stem Cell Workshop 2007, German Society for Autoimmune Diseases. Düsseldorf, Germany. March 2007. L. Chatenoud.
- ▶ "Autoimmune diabetes" 7th world congress on Trauma, shock, inflammation and sepsis-tsis 2007. Munich, Germany. March 2007. L. Chatenoud.
- ▶ "Building on the Experience with CD3-spécific Antibodies to Induce Tolerance in Autoimmunity" FOCIS. San Diego, USA. June 2007. L. Chatenoud.
- ▶ "Dominant peripheral tolerance induced by anti-CD3 therapy. Lessons learned from animal and human diabetes" 8th world congress on inflammation. Copenhagen, Denmark. June 2007. L. Chatenoud.
- ▶ "Immunotherapy of overt autoimmune diabetes" 13th International congress of immunology. Rio de Janeiro, Brazil. August 2007 L. Chatenoud.
- ▶ "Natural versus Adaptive Regulation of immunity" French Academy of Sciences and German Academy of Sciences Leopoldina. Mont Saint-Odile, France. September 2007 L. Chatenoud.
- ▶ "Lessons learned from T1DM prevention trials that could be applied to pancreas and islet transplantation". CTS-IPITA-IXA. Minneapolis, USA. September 2007. L. Chatenoud.
- ▶ "Immune tolerance: myths and realities". French Society of Dermatology. Paris, France, September 2007. L. Chatenoud.
- ▶ "The GITR/GITR ligand pathway in the development of autoimmune diabetes". From the laboratory to the clinic: T cells and cytokines. Oxford, UK. September 2007. L. Chatenoud.

Les conférences (Suite) Communication (Cont.)

- ▶ "Immunointervention in type 1 DM". Spanish society of Diabetology. Alicante, Spain. October 2007. L. Chatenoud.
- ▶ "Adaptive human regulatory cells: myth or reality". 23rd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic. October 2007. L. Chatenoud.
- ▶ "The correlation of immunosuppression and tolerance" 13th congress of ESOT (European Society for Organ Transplantation). Prague, Czech Republic. October 2007. L. Chatenoud.
- ▶ "Defining roles of the immune response in type 1 diabetes. Regulatory and effector T-cell responses in type 1 diabetes" 9th International congress of the immunology of diabetes society and American Diabetes Association research symposium. Miami, USA. November 2007. L. Chatenoud.
- ▶ "Les maladies auto-immunes et la ménopause (lupus érythémateux...). 35^{ème} journées de gynécologie obstétrique et fertilité. Paris, France. Novembre 2007. L. Chatenoud.
- ▶ Immunointervention in a model of AAV-mediated gene transfer into the skeletal muscle of non-human primates. I.Anegon (*Invited speaker*) at the Workshop on overcoming bottlenecks in the development of therapeutics for rare neuromuscular disorders. Géncentre, Evry, France, January 16th 2007.
- ▶ Markers of operational tolerance in human kidney recipients patients. J.P. Souillou (*Invited speaker*)- *Plenary session*. 9^o Congreso Societat Catalana de Trasplantament. Barcelona, Spain, February 25-28th 2007.
- ▶ Kidney transplant activity in France: Inventory and statement. G.Karam (*Invited speaker*). Forum de la section Transplantation de l'association européenne d'urologie, Berlin, March 2007.
- ▶ Tolerogenic effects of heme oxygenase-1 activity on DC function. I.Anegon (*Invited speaker*). 3rd Southern Symposium in Dendritic Cells. University of Uruguay, Montevideo, Uruguay, March 26-29th 2007.
- ▶ Allograft tolerance mediated by CD8+ Treg and IDO. I.Anegon (*Invited speaker*). 1st European IDO Meeting. University of Bonn, Germany, April 18-20th 2007.
- ▶ Characteristics of operationally tolerant renal allograft recipients. J.P.Souillou (*Invited speaker*). World Congress of Nephrology. Rio de Janeiro, Brazil, April 21-25th 2007.
- ▶ Chronic rejection. J.P.Souillou (*Invited speaker*). 21st European Immunogenetics and histocompatibility Conference - EFI (European Federation for Immunogenetics). Barcelona, Spain, May 5-8th 2007.
- ▶ Steroid free immunosuppression after pancreas transplantation. D.Cantarovich (*Invited speaker*). Transplant Meeting of the San Raffaele Hospital. Milano, Italy, May 18th 2007.
- ▶ Immunosuppression et cancer, de la théorie à la pratique. J.Dantal (*Invited speaker*). Symposium Wyeth, Paris, May 23rd 2007.
- ▶ Tolerogenic effects of heme oxygenase-1 activity on DC function. I.Anegon (*Invited speaker*). Seminar at the Cedars-Sinai Medical School, Los Angeles, June 4th, 2007.
- ▶ HO-1 confers tolerogenic effects to dendritic cells. I.Anegon (*Invited speaker*). Seminar at the Institute for Gene Therapy, Cedars-Sinai, Los Angeles, USA, June 5th 2007.
- ▶ Confounding factors in the assessment of long-term kidney graft outcome. M.Giral (*Invited Speaker*). 13th N.A.T. "Surrogate markers for the prediction of long-term outcome in transplantation". Nantes, June 14th and 15th 2007.
- ▶ Surrogate markers for a biological signature of operational tolerance following kidney transplantation. S.Brouard (*Invited Speaker*). The prediction of long-term outcome in transplantation. 13th NAT. Nantes, June 14th and 15th 2007.
- ▶ Tumors / The role of PSI. J.Dantal (*Invited speaker*). Latino American Event, Orlando, USA, June 22-23rd 2007.
- ▶ The Use of Mesenchymal Stem Cells in Restorative Therapy for Neurodegenerative Diseases. L.Lescaudron (*Invited speaker*). The Central Neuroscience Society and Program in Neuroscience, Central Michigan University, Mt Pleasant, MI, U.S.A. July 18th 2007.
- ▶ Development of new animal models of Parkinson's disease. L.Lescaudron (*Invited speaker*). The Central Neuroscience Society and Program in Neuroscience, Central Michigan University, Mt Pleasant, MI, U.S.A. July 25th 2007.
- ▶ Estado actual del trasplante de pancreas. D.Cantarovich (*Invited speaker*). Universidad Catolica de Buenos Aires, Buenos Aires, Argentina, August 10th 2007.
- ▶ Francia trial and Pancreas Study. D.Cantarovich (*Invited speaker*). Instituto de Nefrologia de Buenos Aires. Buenos Aires, Argentina, August 13rd 2007.
- ▶ Spontaneous tolerance to allograft in human: a paradigm for personalized medicine in transplantation, S.Brouard (*Invited speaker*). The 13th International Congress of Immunology 2007 (ImmunoRio2007). Rio de Janeiro, Brazil, August 21-25th 2007.
- ▶ Gene transfer and cellular therapy using heme oxygenase-1 in transplantation models. I.Anegon (*Invited speaker*). The 5th International Congress in heme oxygenases, Krakow, Poland, September 5th, 2007.
- ▶ Predicting the immunological risk in transplantation in humans. J.P Souillou (*Invited speaker*). 37th annual meeting of the German Society for Immunology, Heidelberg, September 5-7th 2007.
- ▶ ATG and minimization of immunosuppression. D.Cantarovich (*Invited speaker*). Annual Meeting of the Hungarian Transplant Society, Budapest, Hongrie, September 7th 2007.
- ▶ Nouvelles perspectives pour le blocage de la costimulation : les anticorps anti-CD 28. B.Vanhove (*Invited speaker*). 9^{ème} réunion commune de la Société de Néphrologie et Société Francophone de Dialyse. Lyon, France, September 11-14th 2007.
- ▶ Biomarkers of Tolerance. Francophone society of bone marrow transplantation, J.Ashton-Chess (*Invited speaker*). Bruxelles, October 2007.
- ▶ The chemokine SDF-1 in neuron development and patterning. Meeting Chemokines and Chemokine Receptors in the Nervous System, Hélène Boudin (*Invited speaker*) Rome, Italie, October 27-28th 2007.
- ▶ Prevencion con Vanganciclovir durante 6 meses despues del trasplante renal. D.Cantarovich (*Invited speaker*). Reunion cientifica en Trasplante renal y renopancreatico, Hospital Publico Argerich, Buenos Aires, Argentina, October 30th 2007.
- ▶ Tacrolimus-based immunosuppression and steroid avoidance following transplantation. D.Cantarovich (*Invited speaker*). Annual meeting of the Niguarda Hospital, Milano, Italy, November 14th 2007.
- ▶ Targeting CD28 with antagonist antibodies for immunomodulation". Key Opinion Leader Meeting of the Transplantation Society, B.Vanhove (*Invited speaker*), Cape Town, South Africa, November 15-18th, 2007.
- ▶ Heme oxygenase-1: an anti-oxidant molecule with anti-inflammatory and tolerogenic properties. I.Anegon (*Invited speaker*). Seminar at the Instituto Pasteur of Montevideo, Uruguay, November 21st, 2007.
- ▶ Tolerant human transplant recipients and the threat of infections J.P. Souillou (*Invited speaker*). Netherlands Transplant Society, Utrecht, Netherlands, November 22nd, 2007.
- ▶ Les marqueurs de la tolérance. Congrès français de pédiatrie, S.Brouard (*Invited speaker*) Nantes, France, November 28-29th 2007.
- ▶ Tolérance Immune en Greffe d'Organes. France Transplant, S.Brouard (*Invited speaker*) Paris, November 28-29th 2007.
- ▶ Actualités sur l'induction de la tolérance. J.P. Souillou (*Invited speaker*). Congrès annuel de la Société de Néphrologie Pédiatrique, Nantes, France, November 30th, 2007
- ▶ Anomalies du bas appareil urinaire et transplantation rénale. G.Karam (*Invited speaker*). Forum du Comité de Transplantation de l'association française d'urologie, Paris, Novembre 2007.

Les programmes de recherche financés

Research programs financed in 2007

- **PHRC (Programme Hospitalier de Recherche Clinique) 2007**
« Dépistage sur puce oligonucléotidique panvirale de virus émergents chez le sujet immunosupprimé après transplantation rénale ou pancréatique »
- **The Dana Foundation**
« Immune-Mediated Inflammatory Diseases Working Group: Evaluation of TNFalpha blockade by monoclonal antibodies in rat allotransplantation models. »
- **Wyeth Pharmaceuticals**
« DNA profiling and peripheral blood immune cell phenotyping of stable renal transplant patients with good graft function on sirolimus monotherapy »
- **INCA (Institut National du Cancer)**
« Protéomique et Cancer n° PBF/06-10 "Multi center evaluation of clustering efficiency : a step to determine the best conditions for protein profiling in prostate cancer and lymphoma »
- Fédération pour la Recherche sur le Cerveau
Appel d'offre 2006
- **Vaindre la Mucoviscidose** (Projet n° FG0615)
« Induction de tolérance par blocage des signaux de costimulation CD28/B7 et CD40/CD40L chez le primate par vectorisation générique »
- **Agence de la Biomédecine**
« Caractérisation de nouveaux biomarqueurs sanguins du rejet chronique chez des patients ayant reçu une greffe rénale »
- **Agence de la Biomédecine**
« Induction de tolérance par blocage des signaux de costimulation CD28 et CD40 chez le primate vectorisation génétique »
- **Agence de la Biomédecine**
« Identification de marqueur(s) protéique(s) sérique(s) du rejet chronique dans un modèle d'allogreffe rénale »
- **Agence de la Biomédecine**
« SMILE, un nouveau biomarqueur du devenir du greffon »
- **Agence de la Biomédecine**
« Développement d'un cross match endothélial post-greffe, spécifique du couple donneur -receveur chez des patients transplantés rénaux »
- **AFM (Association Française contre les Myopathies)** - Appel d'offres 2007
Advantage of cograftering in neurorestorative strategies n° 13064
« Fonctions immunomodulatrices des MSC en xénotransplantation neurale »
- Neo PDGF - Promoteur DRC Amiens
- Tactique - Promoteur DRC Amiens